Advertisement

Uroonkologie pp 595-615 | Cite as

Immuntherapie urologischer Tumoren — Nebenwirkungen und ihre Behandlung

  • T. Ebert
  • T. Vögeli
  • B. J. Schmitz-Dräger

Zusammenfassung

Um neben der Wirksamkeit einer Substanz ihre Sicherheit beurteilen zu können, müssen Nebenwirkungen von zu testenden Medikamenten innerhalb klinischer Studien nach exakt definerten Richtlinien festgehalten werden. Die Sicherheit eines Medikaments wird dabei sowohl anhand klinischer Befunde als auch anhand von Laborparametern gemessen (Schwarz 1990). Dabei wird differenziert zwischen
  • unerwünschten Ereignissen und

  • unerwünschten Arzneimittelwirkungen bzw. Nebenwirkungen gemäß Arzneimittelgesetz.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abrams J, Rayner A, Wiernik P, Parkinson D (1989) High dose Interleukin-2 without lymphokine activated killer cells: inactive in advanced renal call cancer. Proc Am Soc Clin Oncol 30: 380Google Scholar
  2. Aso Y, Tazaki H, Umeda T, Marumo K (1991) Treatment of advanced renal cell carcinoma by systemic low-dose recombinant interleukin-2 In: Debruyne FMJ, Bukowski RM, Pontes JE, Mulder PHM (eds) Immunotherapy of renal cell carcinoma. Springer, Berlin Heidelberg New York Tokyo, pp 91–103Google Scholar
  3. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM (1988) Hypothyroidism after treatment with Interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318: 1557–1563PubMedCrossRefGoogle Scholar
  4. Atzpodien J, Kirchner H (1990) Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 68: 1–11PubMedCrossRefGoogle Scholar
  5. Atzpodien J, Körfer A, Kirchner H (1991) Interleukin-2 and interferon alpha in renal cell carcinoma: the European experience. The second international symposium: immunobiology of renal cell carcinoma. Oct 21 and 22, 1991. Cleveland, Ohio/USAGoogle Scholar
  6. Belldegrun A, Webb DE, Austin HA, Steinberg SM, White DE, Linehan WM, Rosenberg SA (1987) Effects of Interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 106: 817–822PubMedCrossRefGoogle Scholar
  7. Braley-Mullen H, Johnson M, Sharp GC, Kyriakos M (1985) Induction of experimental autoimmune thyroiditis in mice with in vitro activated splenic T cells. Cell Immunol 93: 132–143PubMedCrossRefGoogle Scholar
  8. Bruns P (1888) Die Heilwirkung des Erysipels auf Geschwülste. Beitr Klin Chir 3: 443–466Google Scholar
  9. Bukowski RM, Goodman P, Crawford ED, Sergi JS, Redman BG, Whitehead RP (1990) Phase II trial of high-dose intermittent Interleukin-2 in metastatic renal cell carcinoma: Southwest Oncology Group Study. Reports 82: 143–146Google Scholar
  10. Busch (1868) Verhandlungen Ärztlicher Gesellschaften. Berl Klin Wochenschr 12: 137–138Google Scholar
  11. Buzaid AC, Robertone A, Kisala C, Salmon SE (1987) Phase II study of recombinant interferon alfa-2a ( Roferon-A) in metastatic renal cell carcinoma. J Clin Oncol 5: 1083–1089Google Scholar
  12. Coley WB (1891) Contribution to the knowledge of sarcoma. Ann Surg 14: 199–220PubMedCrossRefGoogle Scholar
  13. Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK (1988) A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 62: 2467–2471PubMedCrossRefGoogle Scholar
  14. DeKernion JB, Sarna G, Figlin R, Lindner A, Smith RB (1983) The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol 130: 1063–1066PubMedGoogle Scholar
  15. Dinarello CA (1989) Interleukin-1 and its biologically related cytokines. Adv. Immunol 44: 153–205PubMedCrossRefGoogle Scholar
  16. Dutcher J (1991) Clinical results with high dose interleukin-2 in the United States. The second international symposium• immunobiology of renal cell carcinoma, October 21 and 22, Celeveland, Ohio/USAGoogle Scholar
  17. Fossa SD (1991) Further experience with high dose interferon alpha and prednisone in metastatic renal cell carcinoma. The second international symposium: immunobiology of renal cell carcinoma, Oct 21 and 22, Cleveland, Ohio/USAGoogle Scholar
  18. Galligioni E, Sorio R, Sacco C et al. (1991) Recombinant Interleukin-2 (rIL2) by continuous infusion in patients with advanced renal cell cancer. The second international symposium: immunobiology of renal cell carcinoma, Oct 21 and 22, Cleveland, OH, USA, p 135Google Scholar
  19. Herr HW, Pinsky CM, Whitmore WF, Sogani PC, Oettgen HF, Melamed MR (1986) Long-term effect of intravesical bacillus calmette-guerin on flat carcinoma in situ of the bladder. J Urol 135: 265–267PubMedGoogle Scholar
  20. Hermann F, Mertelsmann R (1989) Tumornekrosefaktor. Dtsch Med Wochenschr 114: 312–316CrossRefGoogle Scholar
  21. Herrmann F (1990) Die Stellung der Interferone in der Zytokinkaskade. In: Niederle N, Wussow P (Eds) Interferone — Präklinische und klinische Befunde. Springer, Berlin Heidelberg New York Tokyo, S 53–64CrossRefGoogle Scholar
  22. Huland E (1992) IL-2 Inhalation beim pulmonal metastasierten Nierenzell-Ca. Symposium: Immuntherapie in der Uro-Onkologie. 6.-8. Februar 1992, EssenGoogle Scholar
  23. Jacobsen H (1990) Struktur und Wirkung von Interferonen. In: Niederle N, von Wussow P (Eds) Interferone — Präklinische und klinische Befunde. Springer, Berlin Heidelberg New York Tokyo, S 1–44CrossRefGoogle Scholar
  24. Jakubowski AA, Casper ES, Gabrilove JL, Templeton M-A, Sherwin SA, Oettgen HF (1989) Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer. J Clin Oncol 7: 298–303PubMedGoogle Scholar
  25. Khanna OMP, Son DL, Mazer H et al. (1990) Multicenter study of superficial bladder cancer treated with intravesical bacillus calmette-guerin or adriamycin. Urology 35: 101–108PubMedCrossRefGoogle Scholar
  26. Kirkwood JM, Harris JE, Vera R et al. (1985) A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res 45: 863–871PubMedGoogle Scholar
  27. Kragel AH, Travis MD, Feinberg L et al. (1990) Pathologic findings associated with Interleukin-2-based immunotherpy for cancer: A postmortem study of 19 patiens. Hum Pathol 21: 493–502PubMedCrossRefGoogle Scholar
  28. Krown SE, Einzig AI, Abramson JA (1983) Treatment of advanced renal cell cancer with recombinant leukocyte alpha interferon. Proc Am Soc Clin Oncol 2: 58Google Scholar
  29. Kummer G, Kloke O, Niederle N (1990) Interferonrezeptoren: Charakterisierung und mögliche klinische Bedeutung. In: Niederle N, von Wussow P (Eds) Interferone. Prä-klinische und klinische Befunde. Springer, Berlin Heidelberg New York Tokyo, S 65–78CrossRefGoogle Scholar
  30. Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG (1986) Complications of Bacillus Calmette Guérin immunotherapy in 1278 patients with bladder cancer. J Urol 135: 272–274PubMedGoogle Scholar
  31. Lamm DL, Steg A, Boccon-Gibod L et al. (1989) Complications of Bacillus Calmette-Guérin immunotherapy: review of 2602 patients and comparison of chemotherapy complication. In: Debruyne FMJ, Denis L, van der Meijden APM (eds) BCG in superficial bladder cancer. Riss, New York, pp 335–355Google Scholar
  32. Lee RE, Lotze MT, Skibber JM et al. (1989) Cardiorespiratory effects of immunotherapy with Interleukin-2. J Clin Oncol 7: 7–20PubMedGoogle Scholar
  33. Maase H von der, Geertsen P, Thatcher N et al. (1991) Recombinant interleukin-2 in metastatic renal all carcinoma — a European multicenter phase II study. Eur J Cancer 27: 1583–1589PubMedCrossRefGoogle Scholar
  34. Margolin KA, Rayner AA, Hawkins MJ et al. (1989) Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 7: 486–498PubMedGoogle Scholar
  35. Marumo K, Murai M, Hayakawa M, Tazaki H (1984) Human lymphoblastoid interferon therapy for advanced renal cell carcinoma. Urology 6: 567–571CrossRefGoogle Scholar
  36. Marumo K, Muraki J, Ueno M et al. (1989) Immunologic study of human recombinant Interleukin-2 (low-dose) in patients with advanced renal cell carcinoma. Urology 33: 219–225PubMedCrossRefGoogle Scholar
  37. Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116: 180–183PubMedGoogle Scholar
  38. Muss HB, Costanzi JJ, Leavitt R et al. (1987) Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 5: 286–291PubMedGoogle Scholar
  39. Neidhart JA, Gagen MM, Young D, Tuttle R, Melink TJ, Ziccarrelli A, Kisner D (1984) Interferon-alpha therapy of renal cancer. Cancer Res 44: 4140–4143PubMedGoogle Scholar
  40. O’Garra A (1989a) Interleukins and the immune system 1. Lancet 1:943–946 O’Garra A (1989b) Interleukins and the immune system 2. Lancet 1: 1003–1005PubMedCrossRefGoogle Scholar
  41. Orihuela E, Herr HW, Pinsky CM, Whitmore WF (1987) Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 60: 326–333PubMedCrossRefGoogle Scholar
  42. Puri RK, Travis WD, Rosenberg SA (1989) Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo. Cancer Res 49: 969–976PubMedGoogle Scholar
  43. Quesada JR, Swanson DA, Trindade A, Gutterman JU (1983) Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res 43: 940–943PubMedGoogle Scholar
  44. Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU (1985a) Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3: 1522–1528PubMedGoogle Scholar
  45. Quesada JR, Swanson DA, Gutterman JU (1985b) Phase II study of interferon alpha in metastatic renal cell carcinoma: a progress report. J Clin Oncol 3: 1086–1092PubMedGoogle Scholar
  46. Reid I, McDevitt SJ, Emmons MR, Tanner WA, Monson JRT (1991) Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha. Cancer 64: 915–918CrossRefGoogle Scholar
  47. Richards JM, Barker E, Latta J, Ramming K, Vogelzang NJ (1988) Phase I study of weekly 24-hours infusions of recombinant human interleukin-2. J Natl Cancer Inst 80: 1325–1328PubMedCrossRefGoogle Scholar
  48. Rombis V, Gaganakis J, Salfigides G, Hafalamfous S, Anastasiadis G (1989) The treatment of metastatic renal cell carcinoma with alpha-interferon. J 16th Int Cong Chemotherapy, p 14Google Scholar
  49. Rosenberg SA, Lotze MT, Muul LM (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889–897PubMedCrossRefGoogle Scholar
  50. Rosenberg SA, Lotze MT, Yang JC, Uebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose Interleukin-2 in the treatment of 652 patients. Ann Surg: 474–485Google Scholar
  51. Rosenthal FM, Lindemann A, Herrmann F, Mertelsmann R (1991) Zytokine in der Tumortherapie. Die Gelben Hefte 31: 51–60Google Scholar
  52. Samlowski WE, Ward JH, Craven CM, Freedman RA (1989) Severe myocarditis following high-dose Interleukin-2 administration. Arch Pathol Lab Med 113: 838–841PubMedGoogle Scholar
  53. Schwarz JA (1990) Vorschlag für einen Standardprüfplan und eine Patienteneinverständniserklärung. In: Witte PU, Schenk J, Schwarz JA, Kori-Lindner C (Eds) Ordnungsgemäße klinische Prüfung. Habrich, Fürth, S 11–50Google Scholar
  54. Shinka T, Hirano Y, Uekado I, Kyoku I, Aoshi H, Ohkawa T (1989) Intravesical bacillus calmette-guerin treatment for superficial bladder tumours. Br J Urol 63: 610–615PubMedCrossRefGoogle Scholar
  55. Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM (1988) Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 80: 60–63PubMedCrossRefGoogle Scholar
  56. Steineck G, Strander H, Carbin BE et al. (1989) Recombinant leukocyte interferon alpha-2A and medroxyprogesterone in advanced renal cell carcinoma. Acta Oncol 29: 155–162CrossRefGoogle Scholar
  57. Steis RG, Smith JW, Urba WJ et al. (1988) Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing antiinterferon antibodies. N Engl J Med 318: 1409–1413PubMedCrossRefGoogle Scholar
  58. Umeda I, Niijima T (1986) Phase II study of alpha interferon on renal cell carcinoma. Cancer 58: 1231–1235PubMedCrossRefGoogle Scholar
  59. Vetto JT, Papa MZ, Lotze MT, Chang AE, Rosenberg SA (1987) Reduction of toxicity of Interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 5: 496–503PubMedGoogle Scholar
  60. Vugrin D, Hood L, Taylor W, Laszlo J (1985) Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma. Cancer Treat Rep 69: 817–820PubMedGoogle Scholar
  61. Whitehead RP, Ward D, Hemingway L, Hemstreet GP, Bradley E, Konrad M (1990) Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res 50: 6708–6715PubMedGoogle Scholar
  62. Wiedenmann B, Reichard P, Räth U et al. (1989) Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol 115: 189–192PubMedCrossRefGoogle Scholar
  63. Wong GG, Witek-Giannotti JS, Temple TA (1988) Stimulation of murine hemopoietic colony formation by human IL-6. Immunol 140: 3040–3044Google Scholar
  64. Wussow P von, Jakschies D (1990) Interferon-Antikörper — Phantasie oder Faktum. In: Niederle N, Wussow P (Eds) Interferone. Präklinische und klinische Befunde. Springer, Berlin Heidelberg New York Tokyo, S 79–91CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • T. Ebert
  • T. Vögeli
  • B. J. Schmitz-Dräger

There are no affiliations available

Personalised recommendations